查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1750864

Humira市場規模、佔有率、趨勢分析報告：按產品、應用、分銷管道、地區、細分市場預測，2025 年至 2030 年

Humira Market Size, Share & Trends Analysis Report By Product (Branded, Biosimilar), By Application (Rheumatoid Arthritis, Psoriatic Arthritis, Crohn's Disease), By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10個工作天內

價格

Humira市場成長與趨勢

根據Grand View Research, Inc.的最新報告，預計到2030年全球Humira市場規模將達到41.1億美元，預測期內複合年成長率為-11.29%。

儘管下滑，但受全球類風濕性關節炎、克隆氏症和潰瘍性大腸炎等自體免疫疾病盛行率上升的推動，市場需求持續成長。多年來，Humira一直是這些疾病治療的基石，對有效生物製藥的需求仍然強勁。然而，隨著市場動態的變化，生物相似藥的進入和法律規範也在不斷演變。

Humira)市場佔有率的下降主要歸因於生物相似藥的日益普及。隨著關鍵專利到期，以及監管支持和成本控制策略的推動，生物相似藥的供應日益充足，尤其是在新興市場。這促使人們轉向更廉價的替代品，從而增加了生物相似藥的採用率，並擴大了患者的可及性。雖然Humira的療效已得到證實，並且仍然是治療自體免疫疾病的首選藥物，但生物相似藥的日益普及導致價格競爭加劇，削弱了其整體市場主導地位。

儘管市場萎縮，但仍存在巨大的成長機會，尤其是在醫療基礎設施發達、自體免疫疾病認知度不斷提升的新興市場。 Humira適應症的擴大以及無檸檬酸鹽和高濃度注射劑等新劑型的推出，正在推動Humira的持續需求，尤其是在醫療框架和報銷支持更強的地區。

包括艾伯維、安進、山德士和梯瓦等主要生物相似藥製造商在內的製藥公司，正透過策略聯盟、產品差異化和生命週期管理來應對不斷變化的市場格局。儘管生物相似藥將於2024年問世，但艾伯維憑藉其品牌忠誠度、豐富的臨床數據和醫生的信任，仍保持著較高的市場佔有率。

Simlandi 等可互換生物相似藥的上市，以及 Evernorth 零自付費用計劃等近期進展，凸顯了人們對平價醫療服務日益成長的需求。隨著生物相似藥快速核准並持續擴大市場佔有率，Humira)產業的競爭格局也日益活躍。預計Humira市場將繼續發展，主要企業將專注於擴大適應症、改善給藥系統，並滲透到尚未開發的地區，以跟上自體免疫疾病治療領域不斷變化的動態。

Humira市場報告重點

  • 在產品層面，原創品牌產品將佔據市場主導地位，到2024年將達到87.0%的佔有率。這種主導地位歸因於經過驗證的臨床療效、在多種自體免疫疾病方面的廣泛監管核准以及醫生和患者對該品牌的長期信任。
  • 根據應用，類風濕性關節炎將佔據市場主導地位，到 2024 年將佔 20.5% 的佔有率。
  • 根據分銷管道，醫院藥房將引領市場，到 2024 年將佔據 41.0% 的佔有率。對於需要專門治療的患者， Humira是透過醫院開立和配發的首選治療方案。
  • 市場主要企業包括艾伯維、安進、勃林格殷格翰、輝瑞、三星Bioepis、山德士等。競爭愈演愈烈，尤其是隨著Humira關鍵專利到期，市場向廣泛的Adalimumab單抗治療方法開放，生物相似藥製造商的影響力不斷擴大。
  • 2024年6月，Coherus BioSciences揭露已完成將修美樂（Humira）的生物相似藥YUSIMRY以4,000萬美元現金出售給香港健友實業有限公司，該交易於2024年6月26日完成交割。 YUSIMRY將繼續由香港健友實業的子公司美泰製藥（Meitheal Pharmaceuticals）在美國進行商業化。 Coherus表示，此次資產剝離符合公司加強腫瘤產品組合的策略重點。

目錄

第1章調查方法與範圍

第2章執行摘要

第3章Humira市場變數、趨勢與範圍

  • 市場體系展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 商業環境分析
    • 產業分析-波特五力分析
    • PESTLE分析
    • 管道分析
    • 專利到期分析
    • 定價分析

第4章Humira市場：依產品、業務分析

  • 2024 年及 2030 年產品市場佔有率
  • 產品細分儀表板
  • 市場規模、預測與趨勢分析（按產品，2018-2030 年）
  • 原廠產品
  • 生物相似藥

第5章Humira市場：按應用、業務分析

  • 2024 年和 2030 年應用市場佔有率
  • 應用程式細分儀表板
  • 市場規模、預測與趨勢分析（按應用，2018-2030 年）
  • 類風濕性關節炎
  • 乾癬性關節炎
  • 克隆氏症
  • 潰瘍性大腸炎
  • 僵直性脊椎炎
  • 其他

第6章Humira市場：依分銷管道、業務分析

  • 2024年及2030年分銷通路市場佔有率
  • 分銷通路細分儀表板
  • 按分銷管道分類的市場規模、預測和趨勢分析（2018-2030 年）
  • 醫院藥房
  • 零售藥局
  • 網路藥局

第7章Humira市場：區域、估計與趨勢分析

  • 2024 年及 2030 年區域市場佔有率分析
  • 區域市場儀表板
  • 2018-2030年市場規模及預測趨勢分析
  • 北美洲
    • 2018-2030年各國情況
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第8章 競爭態勢

  • 參與者概覽
  • 企業市場分析
  • 公司分類
  • 戰略地圖
  • 公司簡介/上市公司
    • AbbVie
    • Alvotech
    • Amgen Inc.
    • Boehringer Ingelheim Pharmaceuticals Inc.
    • Celltrion Inc.
    • Coherus Biosciences公司
    • Fresenius Kabi AG
    • 富士軟片協和基蘭生物製劑株式會社
    • Pfizer Inc.
    • Samsung Bioepis
    • Sandoz Inc.
Product Code: GVR-4-68040-570-9

Humira Market Growth & Trends:

The global humira market size is projected to reach USD 4.11 billion by 2030, declining at a CAGR of -11.29% during the forecast period, according to a new report by Grand View Research, Inc. Despite this decline, the market continues to experience sustained demand, driven by the rising global prevalence of autoimmune diseases such as rheumatoid arthritis, Crohn's disease, and ulcerative colitis. Humira has long been a cornerstone of treatment for these conditions, and demand for effective biologic therapies remains strong. However, as the market shifts, the entry of biosimilars and evolving regulatory frameworks are reshaping its dynamics.

The decline in Humira's market share is largely attributed to the growing availability of biosimilars. With the expiration of key patents, biosimilars, driven by regulatory support and cost-containment strategies, are becoming increasingly accessible, particularly in emerging markets. As a result, there is a shift towards more affordable alternatives, increasing the adoption of biosimilars and expanding patient access. Although Humira's proven efficacy continues to make it a top choice for managing autoimmune diseases, the increasing presence of biosimilars leads to a competitive pricing environment and reduces its overall market dominance.

Despite the market's decline, significant growth opportunities remain, especially in developing regions where healthcare infrastructure is improving and awareness of autoimmune conditions is rising. The expanding indications for Humira and new formulations, such as citrate-free versions and high-concentration injectables, drive continued demand for the drug, particularly in regions with a strong healthcare framework and reimbursement support.

Pharmaceutical companies, including AbbVie and leading biosimilar manufacturers like Amgen, Sandoz, and Teva, are navigating the evolving landscape through strategic partnerships, product differentiation, and lifecycle management. AbbVie has retained significant market share through brand loyalty, extensive clinical data, and physician trust, despite the emergence of biosimilars in 2024.

Recent developments, such as the launch of interchangeable biosimilars like Simlandi and initiatives like Evernorth's zero out-of-pocket cost program, highlight the growing push for affordable access. As biosimilars rapidly gain approval and expand market presence, the competitive landscape of the Humira industry is becoming increasingly dynamic. The market is expected to continue evolving, with key players focusing on expanding indications, enhancing delivery systems, and penetrating underserved regions to capitalize on the shifting dynamics of autoimmune disease treatment.

Humira Market Report Highlights:

  • Based on product, Branded Humira dominated the market, accounting for 87.0% of the share in 2024. This dominance is attributed to its proven clinical efficacy, wide-ranging regulatory approvals across multiple autoimmune conditions, and long-standing physician and patient trust in the brand.
  • Based on application, rheumatoid arthritis dominated the market and accounted for a share of 20.5% in 2024, driven by its rising global prevalence and increasing adoption of advanced therapies.
  • Based on distribution channel, hospital Pharmacies led the market and accounted for a share of 41.0% in 2024, driven by the growing demand for biologic therapies used in managing autoimmune conditions. Humira is a preferred treatment option prescribed and dispensed through hospital settings for patients requiring specialized care.
  • Key players in the market include AbbVie, Amgen, Boehringer Ingelheim, Pfizer, Samsung Bioepis, and Sandoz. Competition is intensifying with the growing presence of biosimilar manufacturers, especially following the expiration of Humira's key patents, which has opened the market to a broader range of adalimumab-based therapies.
  • In June 2024, Coherus BioSciences revealed it had completed the sale of its Humira biosimilar, YUSIMRY, to Hong Kong King-Friend Industrial Co. Ltd. for USD 40 million in cash, with the transaction closing on June 26, 2024. YUSIMRY will continue to be commercialized in the U.S. by Meitheal Pharmaceuticals, a subsidiary of HKF. Coherus noted that the divestiture aligns with its strategic focus on advancing its oncology portfolio.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Product
    • 1.2.2. Application
    • 1.2.3. Distribution Channel
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Humira Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis
    • 3.3.3. Pipeline Analysis
    • 3.3.4. Patent Expiry Analysis
    • 3.3.5. Pricing Analysis

Chapter 4. Humira Market: Product Business Analysis

  • 4.1. Product Market Share, 2024 & 2030
  • 4.2. Product Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Product, 2018 to 2030 (USD Million)
  • 4.4. Branded
    • 4.4.1. Branded Market, 2018 - 2030 (USD Million)
  • 4.5. Biosimilar
    • 4.5.1. Biosimilar Market, 2018 - 2030 (USD Million)

Chapter 5. Humira Market: Application Business Analysis

  • 5.1. Application Market Share, 2024 & 2030
  • 5.2. Application Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Application, 2018 to 2030 (USD Million)
  • 5.4. Rheumatoid Arthritis
    • 5.4.1. Rheumatoid Arthritis Market, 2018 - 2030 (USD Million)
  • 5.5. Psoriatic Arthritis
    • 5.5.1. Psoriatic Arthritis Market, 2018 - 2030 (USD Million)
  • 5.6. Crohn's Disease
    • 5.6.1. Crohn's Disease Market, 2018 - 2030 (USD Million)
  • 5.7. Ulcerative Colitis
    • 5.7.1. Ulcerative Colitis Market, 2018 - 2030 (USD Million)
  • 5.8. Ankylosing Spondylitis
    • 5.8.1. Ankylosing Spondylitis Market, 2018 - 2030 (USD Million)
  • 5.9. Others
    • 5.9.1. Others Market, 2018 - 2030 (USD Million)

Chapter 6. Humira Market: Distribution Channel Business Analysis

  • 6.1. Distribution Channel Market Share, 2024 & 2030
  • 6.2. Distribution Channel Segment Dashboard
  • 6.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2018 to 2030 (USD Million)
  • 6.4. Hospital Pharmacies
    • 6.4.1. Hospital Pharmacies Market, 2018 - 2030 (USD Million)
  • 6.5. Retail Pharmacies
    • 6.5.1. Retail Pharmacies Market, 2018 - 2030 (USD Million)
  • 6.6. Online Pharmacies
    • 6.6.1. Online Pharmacies Market, 2018 - 2030 (USD Million)

Chapter 7. Humira Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Share Analysis, 2024 & 2030
  • 7.2. Regional Market Dashboard
  • 7.3. Market Size & Forecasts Trend Analysis, 2018 to 2030:
  • 7.4. North America
    • 7.4.1. North America Humira Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 7.4.2. U.S.
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Target Disease Prevalence
      • 7.4.2.3. Regulatory Framework
      • 7.4.2.4. Reimbursement Framework
      • 7.4.2.5. U.S. Humira Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.3. Canada
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Target Disease Prevalence
      • 7.4.3.3. Regulatory Framework
      • 7.4.3.4. Reimbursement Framework
      • 7.4.3.5. U.S. Humira Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.4. Mexico
      • 7.4.4.1. Key Country Dynamics
      • 7.4.4.2. Target Disease Prevalence
      • 7.4.4.3. Regulatory Framework
      • 7.4.4.4. Reimbursement Framework
      • 7.4.4.5. Mexico Humira Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5. Europe
    • 7.5.1. Europe Humira Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.2. UK
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Target Disease Prevalence
      • 7.5.2.3. Regulatory Framework
      • 7.5.2.4. Reimbursement Framework
      • 7.5.2.5. Uk Humira Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.3. Germany
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Target Disease Prevalence
      • 7.5.3.3. Regulatory Framework
      • 7.5.3.4. Reimbursement Framework
      • 7.5.3.5. Germany Humira Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.4. France
      • 7.5.4.1. Key Country Dynamics
      • 7.5.4.2. Target Disease Prevalence
      • 7.5.4.3. Regulatory Framework
      • 7.5.4.4. Reimbursement Framework
      • 7.5.4.5. France Humira Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.5. Italy
      • 7.5.5.1. Key Country Dynamics
      • 7.5.5.2. Target Disease Prevalence
      • 7.5.5.3. Regulatory Framework
      • 7.5.5.4. Reimbursement Framework
      • 7.5.5.5. Italy Humira Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.6. Spain
      • 7.5.6.1. Key Country Dynamics
      • 7.5.6.2. Target Disease Prevalence
      • 7.5.6.3. Regulatory Framework
      • 7.5.6.4. Reimbursement Framework
      • 7.5.6.5. Spain Humira Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.7. Denmark
      • 7.5.7.1. Key Country Dynamics
      • 7.5.7.2. Target Disease Prevalence
      • 7.5.7.3. Regulatory Framework
      • 7.5.7.4. Reimbursement Framework
      • 7.5.7.5. Denmark Humira Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.8. Sweden
      • 7.5.8.1. Key Country Dynamics
      • 7.5.8.2. Target Disease Prevalence
      • 7.5.8.3. Regulatory Framework
      • 7.5.8.4. Reimbursement Framework
      • 7.5.8.5. Sweden Humira Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.9. Norway
      • 7.5.9.1. Key Country Dynamics
      • 7.5.9.2. Target Disease Prevalence
      • 7.5.9.3. Regulatory Framework
      • 7.5.9.4. Reimbursement Framework
      • 7.5.9.5. Norway Humira Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6. Asia Pacific
    • 7.6.1. Asia Pacific Humira Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.2. Japan
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Target Disease Prevalence
      • 7.6.2.3. Regulatory Framework
      • 7.6.2.4. Reimbursement Framework
      • 7.6.2.5. Japan Humira Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.3. China
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Target Disease Prevalence
      • 7.6.3.3. Regulatory Framework
      • 7.6.3.4. Reimbursement Framework
      • 7.6.3.5. China Humira Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.4. India
      • 7.6.4.1. Key Country Dynamics
      • 7.6.4.2. Target Disease Prevalence
      • 7.6.4.3. Regulatory Framework
      • 7.6.4.4. Reimbursement Framework
      • 7.6.4.5. India Humira Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.5. Australia
      • 7.6.5.1. Key Country Dynamics
      • 7.6.5.2. Target Disease Prevalence
      • 7.6.5.3. Regulatory Framework
      • 7.6.5.4. Reimbursement Framework
      • 7.6.5.5. Australia Humira Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.6. South Korea
      • 7.6.6.1. Key Country Dynamics
      • 7.6.6.2. Target Disease Prevalence
      • 7.6.6.3. Regulatory Framework
      • 7.6.6.4. Reimbursement Framework
      • 7.6.6.5. South Korea Humira Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.7. Thailand
      • 7.6.7.1. Key Country Dynamics
      • 7.6.7.2. Target Disease Prevalence
      • 7.6.7.3. Regulatory Framework
      • 7.6.7.4. Reimbursement Framework
      • 7.6.7.5. Thailand Humira Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.7. Latin America
    • 7.7.1. Latin America Humira Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.7.2. Brazil
      • 7.7.2.1. Key Country Dynamics
      • 7.7.2.2. Target Disease Prevalence
      • 7.7.2.3. Regulatory Framework
      • 7.7.2.4. Reimbursement Framework
      • 7.7.2.5. Japan Humira Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.7.3. Argentina
      • 7.7.3.1. Key Country Dynamics
      • 7.7.3.2. Target Disease Prevalence
      • 7.7.3.3. Regulatory Framework
      • 7.7.3.4. Reimbursement Framework
      • 7.7.3.5. China Humira Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.8. Middle East and Africa
    • 7.8.1. Middle East and Africa Humira Market Estimates and Forecasts, 2017 - 2030 (USD Million)
    • 7.8.2. South Africa
      • 7.8.2.1. Key Country Dynamics
      • 7.8.2.2. Target Disease Prevalence
      • 7.8.2.3. Regulatory Framework
      • 7.8.2.4. Reimbursement Framework
      • 7.8.2.5. South Africa Humira Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.8.3. Saudi Arabia
      • 7.8.3.1. Key Country Dynamics
      • 7.8.3.2. Target Disease Prevalence
      • 7.8.3.3. Regulatory Framework
      • 7.8.3.4. Reimbursement Framework
      • 7.8.3.5. Saudi Arabia Humira Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.8.4. UAE
      • 7.8.4.1. Key Country Dynamics
      • 7.8.4.2. Target Disease Prevalence
      • 7.8.4.3. Regulatory Framework
      • 7.8.4.4. Reimbursement Framework
      • 7.8.4.5. UAE Humira Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.8.5. Kuwait
      • 7.8.5.1. Key Country Dynamics
      • 7.8.5.2. Target Disease Prevalence
      • 7.8.5.3. Regulatory Framework
      • 7.8.5.4. Reimbursement Framework
      • 7.8.5.5. Kuwait Humira Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Participant Overview
  • 8.2. Company Market Position Analysis
  • 8.3. Company Categorization
  • 8.4. Strategy Mapping
  • 8.5. Company Profiles/Listing
    • 8.5.1. AbbVie
      • 8.5.1.1. Overview
      • 8.5.1.2. Financial Performance
      • 8.5.1.3. Product Benchmarking
      • 8.5.1.4. Strategic Initiatives
    • 8.5.2. Alvotech
      • 8.5.2.1. Overview
      • 8.5.2.2. Financial Performance
      • 8.5.2.3. Product Benchmarking
      • 8.5.2.4. Strategic Initiatives
    • 8.5.3. Amgen Inc.
      • 8.5.3.1. Overview
      • 8.5.3.2. Financial Performance
      • 8.5.3.3. Product Benchmarking
      • 8.5.3.4. Strategic Initiatives
    • 8.5.4. Boehringer Ingelheim Pharmaceuticals Inc.
      • 8.5.4.1. Overview
      • 8.5.4.2. Financial Performance
      • 8.5.4.3. Product Benchmarking
      • 8.5.4.4. Strategic Initiatives
    • 8.5.5. Celltrion Inc.
      • 8.5.5.1. Overview
      • 8.5.5.2. Financial Performance
      • 8.5.5.3. Product Benchmarking
      • 8.5.5.4. Strategic Initiatives
    • 8.5.6. Coherus Biosciences, Inc
      • 8.5.6.1. Overview
      • 8.5.6.2. Financial Performance
      • 8.5.6.3. Product Benchmarking
      • 8.5.6.4. Strategic Initiatives
    • 8.5.7. Fresenius Kabi AG
      • 8.5.7.1. Overview
      • 8.5.7.2. Financial Performance
      • 8.5.7.3. Product Benchmarking
      • 8.5.7.4. Strategic Initiatives
    • 8.5.8. Fujiflim Kyowa Kiran Biologics Co., Ltd.
      • 8.5.8.1. Overview
      • 8.5.8.2. Financial Performance
      • 8.5.8.3. Product Benchmarking
      • 8.5.8.4. Strategic Initiatives
    • 8.5.9. Pfizer Inc.
      • 8.5.9.1. Overview
      • 8.5.9.2. Financial Performance
      • 8.5.9.3. Product Benchmarking
      • 8.5.9.4. Strategic Initiatives
    • 8.5.10. Samsung Bioepis
      • 8.5.10.1. Overview
      • 8.5.10.2. Financial Performance
      • 8.5.10.3. Product Benchmarking
      • 8.5.10.4. Strategic Initiatives
    • 8.5.11. Sandoz Inc.
      • 8.5.11.1. Overview
      • 8.5.11.2. Financial Performance
      • 8.5.11.3. Product Benchmarking
      • 8.5.11.4. Strategic Initiatives

List of Tables

  • Table 1. List of secondary sources
  • Table 2. List of abbreviations
  • Table 3. Global Humira market, by region, 2018 - 2030 (USD Million)
  • Table 4. Global Humira market, by product, 2018 - 2030 (USD Million)
  • Table 5. Global Humira market, by application, 2018 - 2030 (USD Million)
  • Table 6. Global Humira market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 7. North America Humira market, by country, 2018 - 2030 (USD Million)
  • Table 8. North America Humira market, by product, 2018 - 2030 (USD Million)
  • Table 9. North America Humira market, by application, 2018 - 2030 (USD Million)
  • Table 10. North America Humira market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 11. U.S. Humira market, by product, 2018 - 2030 (USD Million)
  • Table 12. U.S. Humira market, by application, 2018 - 2030 (USD Million)
  • Table 13. U.S. Humira market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 14. Canada Humira market, by product, 2018 - 2030 (USD Million)
  • Table 15. Canada Humira market, by application, 2018 - 2030 (USD Million)
  • Table 16. Canada Humira market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 17. Mexico Humira market, by product, 2018 - 2030 (USD Million)
  • Table 18. Mexico Humira market, by application, 2018 - 2030 (USD Million)
  • Table 19. Mexico Humira market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 20. Europe Humira market, by country, 2018 - 2030 (USD Million)
  • Table 21. Europe Humira market, by product, 2018 - 2030 (USD Million)
  • Table 22. Europe Humira market, by application, 2018 - 2030 (USD Million)
  • Table 23. Europe Humira market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 24. UK Humira market, by product, 2018 - 2030 (USD Million)
  • Table 25. UK Humira market, by application, 2018 - 2030 (USD Million)
  • Table 26. UK Humira market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 27. Germany Humira market, by product, 2018 - 2030 (USD Million)
  • Table 28. Germany Humira market, by application, 2018 - 2030 (USD Million)
  • Table 29. Germany Humira market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 30. France Humira market, by product, 2018 - 2030 (USD Million)
  • Table 31. France Humira market, by application, 2018 - 2030 (USD Million)
  • Table 32. France Humira market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 33. Italy Humira market, by product, 2018 - 2030 (USD Million)
  • Table 34. Italy Humira market, by application, 2018 - 2030 (USD Million)
  • Table 35. Italy Humira market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 36. Spain Humira market, by product, 2018 - 2030 (USD Million)
  • Table 37. Spain Humira market, by application, 2018 - 2030 (USD Million)
  • Table 38. Spain Humira market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 39. Norway Humira market, by product, 2018 - 2030 (USD Million)
  • Table 40. Norway Humira market, by application, 2018 - 2030 (USD Million)
  • Table 41. Norway Humira market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 42. Denmark Humira market, by product, 2018 - 2030 (USD Million)
  • Table 43. Denmark Humira market, by application, 2018 - 2030 (USD Million)
  • Table 44. Denmark Humira market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 45. Sweden Humira market, by product, 2018 - 2030 (USD Million)
  • Table 46. Sweden Humira market, by application, 2018 - 2030 (USD Million)
  • Table 47. Sweden Humira market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 48. Asia Pacific Humira market, by country, 2018 - 2030 (USD Million)
  • Table 49. Asia Pacific Humira market, by product, 2018 - 2030 (USD Million)
  • Table 50. Asia Pacific Humira market, by application, 2018 - 2030 (USD Million)
  • Table 51. Asia Pacific Humira market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 52. Japan Humira market, by product, 2018 - 2030 (USD Million)
  • Table 53. Japan Humira market, by application, 2018 - 2030 (USD Million)
  • Table 54. Japan Humira market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 55. China Humira market, by product, 2018 - 2030 (USD Million)
  • Table 56. China Humira market, by application, 2018 - 2030 (USD Million)
  • Table 57. China Humira market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 58. India Humira market, by product, 2018 - 2030 (USD Million)
  • Table 59. India Humira market, by application, 2018 - 2030 (USD Million)
  • Table 60. India Humira market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 61. Australia Humira market, by product, 2018 - 2030 (USD Million)
  • Table 62. Australia Humira market, by application, 2018 - 2030 (USD Million)
  • Table 63. Australia Humira market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 64. South Korea Humira market, by product, 2018 - 2030 (USD Million)
  • Table 65. South Korea Humira market, by application, 2018 - 2030 (USD Million)
  • Table 66. South Korea Humira market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 67. Thailand Humira market, by product, 2018 - 2030 (USD Million)
  • Table 68. Thailand Humira market, by application, 2018 - 2030 (USD Million)
  • Table 69. Thailand Humira market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 70. Latin America Humira market, by country, 2018 - 2030 (USD Million)
  • Table 71. Latin America Humira market, by product, 2018 - 2030 (USD Million)
  • Table 72. Latin America Humira market, by application, 2018 - 2030 (USD Million)
  • Table 73. Latin America Humira market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 74. Brazil Humira market, by product, 2018 - 2030 (USD Million)
  • Table 75. Brazil Humira market, by application, 2018 - 2030 (USD Million)
  • Table 76. Brazil Humira market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 77. Argentina Humira market, by product, 2018 - 2030 (USD Million)
  • Table 78. Argentina Humira market, by application, 2018 - 2030 (USD Million)
  • Table 79. Argentina Humira market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 80. Middle East & Africa Humira market, by country, 2018 - 2030 (USD Million)
  • Table 81. Middle East & Africa Humira market, by product, 2018 - 2030 (USD Million)
  • Table 82. Middle East & Africa Humira market, by application, 2018 - 2030 (USD Million)
  • Table 83. Middle East & Africa Humira market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 84. South Africa Humira market, by product, 2018 - 2030 (USD Million)
  • Table 85. South Africa Humira market, by application, 2018 - 2030 (USD Million)
  • Table 86. South Africa Humira market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 87. Saudi Arabia Humira market, by product, 2018 - 2030 (USD Million)
  • Table 88. Saudi Arabia Humira market, by application, 2018 - 2030 (USD Million)
  • Table 89. Saudi Arabia Humira market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 90. UAE Humira market, by product, 2018 - 2030 (USD Million)
  • Table 91. UAE Humira market, by application, 2018 - 2030 (USD Million)
  • Table 92. UAE Humira market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 93. Kuwait Humira market, by product, 2018 - 2030 (USD Million)
  • Table 94. Kuwait Humira market, by application, 2018 - 2030 (USD Million)
  • Table 95. Kuwait Humira market, by distribution channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Humira market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Therapeutic approach and application outlook (USD Million)
  • Fig. 10 Competitive landscape
  • Fig. 11 Humira market dynamics
  • Fig. 12 Humira market: Porter's five forces analysis
  • Fig. 13 Humira market: PESTLE analysis
  • Fig. 14 Product market, 2018 - 2030 (USD Million)
  • Fig. 15 Branded market, 2018 - 2030 (USD Million)
  • Fig. 16 Biosimilar market, 2018 - 2030 (USD Million)
  • Fig. 17 Application market, 2018 - 2030 (USD Million)
  • Fig. 18 Rheumatoid Arthritis market, 2018 - 2030 (USD Million)
  • Fig. 19 Psoriatic Arthritis market, 2018 - 2030 (USD Million)
  • Fig. 20 Crohn's Diseases market, 2018 - 2030 (USD Million)
  • Fig. 21 Ulcerative Colitis market, 2018 - 2030 (USD Million)
  • Fig. 22 Ankylosing Spondylitis market, 2018 - 2030 (USD Million)
  • Fig. 23 Others market, 2018 - 2030 (USD Million)
  • Fig. 24 Distribution Channel market, 2018 - 2030 (USD Million)
  • Fig. 25 Hospital Pharmacies market, 2018 - 2030 (USD Million)
  • Fig. 26 Retail Pharmacies market, 2018 - 2030 (USD Million)
  • Fig. 27 Online Pharmacies market, 2018 - 2030 (USD Million)
  • Fig. 28 Humira market revenue, by region
  • Fig. 29 Regional marketplace: Key takeaways
  • Fig. 30 Regional marketplace: Key takeaways
  • Fig. 31 North America Humira market, 2018 - 2030 (USD Million)
  • Fig. 32 U.S. country dynamics
  • Fig. 33 U.S. Humira market, 2018 - 2030 (USD Million)
  • Fig. 34 Canada country dynamics
  • Fig. 35 Canada Humira market, 2018 - 2030 (USD Million)
  • Fig. 36 Mexico country dynamics
  • Fig. 37 Mexico Humira market, 2018 - 2030 (USD Million)
  • Fig. 38 Europe Humira market, 2018 - 2030 (USD Million)
  • Fig. 39 UK country dynamics
  • Fig. 40 UK Humira market, 2018 - 2030 (USD Million)
  • Fig. 41 Germany country dynamics
  • Fig. 42 Germany Humira market, 2018 - 2030 (USD Million)
  • Fig. 43 France country dynamics
  • Fig. 44 France Humira market, 2018 - 2030 (USD Million)
  • Fig. 45 Italy country dynamics
  • Fig. 46 Italy Humira market, 2018 - 2030 (USD Million)
  • Fig. 47 Spain country dynamics
  • Fig. 48 Spain Humira market, 2018 - 2030 (USD Million)
  • Fig. 49 Norway country dynamics
  • Fig. 50 Norway Humira market, 2018 - 2030 (USD Million)
  • Fig. 51 Sweden country dynamics
  • Fig. 52 Sweden Humira market, 2018 - 2030 (USD Million)
  • Fig. 53 Denmark country dynamics
  • Fig. 54 Denmark Humira market, 2018 - 2030 (USD Million)
  • Fig. 55 Asia Pacific Humira market, 2018 - 2030 (USD Million)
  • Fig. 56 Japan country dynamics
  • Fig. 57 Japan Humira market, 2018 - 2030 (USD Million)
  • Fig. 58 China country dynamics
  • Fig. 59 China Humira market, 2018 - 2030 (USD Million)
  • Fig. 60 India country dynamics
  • Fig. 61 India Humira market, 2018 - 2030 (USD Million)
  • Fig. 62 Australia country dynamics
  • Fig. 63 Australia Humira market, 2018 - 2030 (USD Million)
  • Fig. 64 South Korea country dynamics
  • Fig. 65 South Korea Humira market, 2018 - 2030 (USD Million)
  • Fig. 66 Thailand country dynamics
  • Fig. 67 Thailand Humira market, 2018 - 2030 (USD Million)
  • Fig. 68 Latin America Humira market, 2018 - 2030 (USD Million)
  • Fig. 69 Brazil country dynamics
  • Fig. 70 Brazil Humira market, 2018 - 2030 (USD Million)
  • Fig. 71 Argentina country dynamics
  • Fig. 72 Argentina Humira market, 2018 - 2030 (USD Million)
  • Fig. 73 MEA Humira market, 2018 - 2030 (USD Million)
  • Fig. 74 South Africa country dynamics
  • Fig. 75 South Africa Humira market, 2018 - 2030 (USD Million)
  • Fig. 76 Saudi Arabia country dynamics
  • Fig. 77 Saudi Arabia Humira market, 2018 - 2030 (USD Million)
  • Fig. 78 UAE country dynamics
  • Fig. 79 UAE Humira market, 2018 - 2030 (USD Million)
  • Fig. 80 Kuwait country dynamics
  • Fig. 81 Kuwait Humira market, 2018 - 2030 (USD Million)
  • Fig. 82 Company categorization
  • Fig. 83 Company market position analysis
  • Fig. 84 Strategic framework